ADR120S rebounds on launch of regenerative medicine service 'NeoCella' in July
ADR120S,Inc. <3750> shares rebounded. After the close on June 2, the company announced the July launch of its regenerative medicine service "NeoCella," triggering positive market sentiment.
"NeoCella" is a regenerative medicine service brand for medical institutions, utilizing the company’s specialized equipment, disposable products, and technologies. ADR120S will supply these products to partner institutions to support the expansion of their services. The impact on earnings for the fiscal year ending March 2027 is under review.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
-
NEXT FUNDS Nikkei225 2x surges into uncharted territory as margin buying balance plunges, margin ratio falls below 1x
Wed Jun 3, 2026 1:18 pm JST Catalyst -
JX Advanced Metals ranks 5th in rising sell forecasts among individual investors on Minkabu
Wed Jun 3, 2026 1:04 pm JST Catalyst -
Star seeds expands gains on upward revision of H1 earnings forecast driven by grid-scale battery business exceeding expectations
Wed Jun 3, 2026 1:12 pm JST Catalyst -
TOSNET CORPORATION rises on launch of AI-powered security service
Wed Jun 3, 2026 12:56 pm JST Catalyst -
1,064 gainers vs 457 decliners on TSE Prime as of 1 p.m.
Wed Jun 3, 2026 1:03 pm JST Market -
Mitsubishi Kakoki Kaisha surges on acquisition of centrifuge maker Saito Enshinki Kogyo
Wed Jun 3, 2026 12:40 pm JST Catalyst -
TOPIX surpasses 4,000 mark for first time in history
Wed Jun 3, 2026 12:42 pm JST Market -
Rasa Industries surges over 23% to daily limit, in spotlight as key TSMC-related stock
Wed Jun 3, 2026 12:34 pm JST Catalyst -
Tokyo stocks mixed around morning close as Nikkei 225 hovers near previous session levels
Wed Jun 3, 2026 12:31 pm JST Market -
Trial Holdings ranks 4th in rising buy predictions from individual investors on Minkabu
Wed Jun 3, 2026 11:35 am JST Catalyst